Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study

[1]  G. Ossenkoppele.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[2]  E. Estey,et al.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jian Huang,et al.  Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms , 2016, Leukemia & lymphoma.

[4]  Bas J. Wouters,et al.  Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. , 2016, Blood.

[5]  Arnaud Pigneux,et al.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. , 2015, The Lancet. Oncology.

[6]  R. Schlenk,et al.  How I treat refractory and early relapsed acute myeloid leukemia. , 2015, Blood.

[7]  G. Roboz.  Epigenetic targeting and personalized approaches for AML. , 2014, Hematology. American Society of Hematology. Education Program.

[8]  J. Lancet,et al.  Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. , 2014, Leukemia research.

[9]  P. Kearns,et al.  Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia , 2014, PloS one.

[10]  F. Ravandi.  Relapsed acute myeloid leukemia: why is there no standard of care? , 2013, Best practice & research. Clinical haematology.

[11]  E. Estey.  Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia , 2013, Leukemia.

[12]  O. Abdel-Wahab,et al.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. , 2013, Blood.

[13]  F. Ferrara,et al.  Acute myeloid leukaemia in adults , 2013, The Lancet.

[14]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[15]  Xiao Li,et al.  Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia , 2012, Annals of Hematology.

[16]  H. Matsuoka,et al.  Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin , 2012, Leukemia.

[17]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Estey,et al.  Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia , 2011, British journal of haematology.

[19]  J. Scandura,et al.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. , 2011, Blood.

[20]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Estey,et al.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. , 2010, Blood.

[22]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[23]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[24]  T. Robak,et al.  Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group , 2007, European journal of haematology.

[25]  J. Issa,et al.  Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines , 2007, Clinical Cancer Research.

[26]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Willemze,et al.  The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature , 2002, Leukemia & lymphoma.

[28]  H. Kantarjian,et al.  A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.

[29]  F. Mandelli,et al.  Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.